Azithromycin reduces the viability of human bronchial smooth muscle cells

Journal of Antibiotics

Volumn 63, Issue 2, 2010, Pages 71-75

  Stamatiou, Rodopi ^a   Boukas, Konstantinos ^a   Paraskeva, Efrosyni ^a   Molyvdas, Paschalis Adam ^a   Hatziefthimiou, Apostolia ^a  

^a UNIVERSITY OF THESSALY   (Greece)

Author keywords

Apoptosis; Autophagy; Azithromycin; Human bronchial SMCs; Viability

Indexed keywords

3 METHYLADENINE; ANNEXIN; AZITHROMYCIN;

APOPTOSIS; ARTICLE; AUTOPHAGY; BRONCHUS MUSCLE; CELL COUNT; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; LYSOSOME; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER;

ANIMALS; ANTI-BACTERIAL AGENTS; APOPTOSIS; AZITHROMYCIN; BRONCHI; CATTLE; CELL LINE; CELL SURVIVAL; HUMANS; MYOCYTES, SMOOTH MUSCLE; RABBITS;

BOVINAE; ORYCTOLAGUS CUNICULUS;

EID: 77950233254     PISSN: 00218820     EISSN: None     Source Type: Journal    
DOI: 10.1038/ja.2009.125     Document Type: Article

References (31)

1. Kudoh, S., Azuma, A., Yamamoto, M., Izumi, T. & Ando, M. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am. J. Respir. Crit. Care Med. 157, 1829-1832 (1998).
2. Oishi,K.et al. Role of interleukin-8 (IL-8) and an inhibitory effect of erythromycin on IL-8 release in the airway of patients with chronic airway diseases. Infect. Immun. 62, 4145-4152 (1994).
3. Shirai, T., Sato, A. & Chida, K. Effect of 14-membered ring macrolide therapy on chronic respiratory tract infections and polymorphonuclear leukocyte activity. Intern. Med. 34, 469-474 (1995).
4. Miyatake, H. et al. Erythromycin reduces the severity of bronchial hyperresponsiveness in asthma. Chest 99, 670-673 (1991).
5. Cazzola, M., Salzillo, A. & Diamare, F. Potential role of macrolides in the treatment of asthma. Monaldi. Arch. Chest Dis. 55, 231-236 (2000).
6. Vignola,A. et al. Airway remodelling in asthma. Chest 123, 417S-422S (2003).
7. Jeffery, P. K. Remodeling in asthma and chronic obstructive lung disease. Am. J. Respir. Crit. Care Med. 164, S28-S38 (2001).
8. Daenas, C., Hatziefthimiou, A. A., Gourgoulianis, K. I. & Molyvdas, P. A. Azithromycin has a direct relaxant effect on precontracted airway smooth muscle. Eur. J. Pharmacol. 553, 280-287 (2006).
9. Stamatiou, R. et al. Azithromycin has an antiproliferative and autophagic effect on airway smooth muscle cells. Eur. Respir. J. 34, 1-11 (2009).
10. Cory, A. H., Owen, T. C., Barltrop, J. A. & Cory, J. G. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun. 3, 207-212 (1991).
11. Berridge, M. V. & Tan, A. S. Characterization of the cellular reduction of 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction. Arch. Biochem. Biophys. 303, 474-482 (1993).
12. Shen, Z. Y. et al. Autophagy and endocytosis in the amnion. J. Struct. Biol. 162, 197-204 (2008).
13. Seglen, P. O. & Gordon, P. B. 3-Methyladenine: specific inhibitor of autophagic/ lysosomal protein degradation in isolated rat hepatocytes. Proc. Natl Acad. Sci. USA 79, 1889-1892 (1982).
14. Petiot, A., Ogier-Denis, E., Blommaart, E. F., Meijer, A. J. & Codogno, P. Distinct classes of phosphatidylinositol 3¢-kinases are involved in signalling pathways that control macroautophagy in HT-29 cells. J. Biol. Chem. 275, 992-998 (2000).
15. Hirst, S. J., Walker, T. R. & Chilvers, E. R. Phenotypic diversity and molecular mechanisms of airway smooth muscle proliferation in asthma. Eur. Respir. J. 16, 159-177 (2000).
16. Bentley, J. K. & Hershenson, M. B. Airway smooth muscle growth in asthma: proliferation, hypertrophy, and migration. Proc. Am. Thorac. Soc. 5, 89-96 (2008).
17. Halayko, A. J. & Amrani, Y. Mechanisms of inflammation-mediated airway smooth muscle plasticity and airways remodeling in asthma. Physiol. Neurobiol. 137, 209-222 (2003).
18. Tomita, H. et al. Roxithromycin is an inhibitor of human coronary artery smooth muscle cells proliferation: a potential ability to prevent coronary heart disease. Atherosclerosis 182, 87-95 (2005).
19. Fujitani, Y. & Trifilieff, A. In vivo and in vitro effects of SAR 943, a rapamycin analogue, on airway inflammation and remodeling. Am. J. Respir. Crit. Care Med. 167, 193-198 (2003).
20. Buitrago-Molina, L. E. et al. Rapamycin delays tumor development in murine livers by inhibiting proliferation of hepatocytes with dna damage. Hepatology 50, 2 (2009).
21. Takahashi, Y., Shimizu, T. & Sakakura, Y. Effects of indomethacin, dexamethasone, and erythromycin on endotoxin-induced intraepithelial mucus production of rat nasal epithelium. Ann. Otol. Rhinol. Laryngol. 106, 683-687 (1997).
22. Roche, Y., Gougerot-Pocidalo, M. A., Fay, M., Forest, N. & Pocidalo, J. J. Macrolides and immunity: effects of erythromycin and spiramycin on human mononuclear cell proliferation. J. Antimicrob. Chemother. 17, 195-203 (1986).
23. Mizunoe, S. et al. Clarithromycin and azithromycin induce apoptosis of activated lymphocytes via down-regulation of Bcl-xL. Int. Immunopharmacol. 4, 1201-1207 (2004).
24. Cui, Q., Tashiro, S., Onodera, S., Minami, M. & Ikejima, T. Autophagy preceded apoptosis in oridonin-treated human breast cancer MCF-7 cells. Biol. Pharm. Bull. 30, 859-864 (2007).
25. Yan, C. H. et al. Autophagy is involved in cytotoxic effects of crotoxin in human breast cancer cell line MCF-7 cells. Acta. Pharmacol. Sin. 28, 540-548 (2007).
26. Shacka, J. et al. Bafilomycin A1 inhibits cloroquine-induced death of celebellar granule neurons. Mol. Pharmacol. 69, 1125-1136 (2006).
27. Canu, N. et al. Role of the autophagic-lysosomal system on low potassiuminduced apoptosis in cultured cerebellar granule cells. J. Neurochem. 92, 1228-1242 (2005).
28. Shimizu, T., Shimizu, S., Hattori, R., Gabazza, E. C. & Majima, Y. In vivo and in vitro effects of macrolide antibiotics on mucus secretion in airway epithelial cells. Am. J. Respir. Crit. Care Med. 168, 581-587 (2003).
29. Danesi, R. et al. Comparative distribution of azithromycin in lung tissue of patients given oral daily doses of 500 and 1000mg. J. Antimicrob. Chemother. 51, 939-945 (2003).
30. Patel, K. B. et al. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob. Agents Chemother. 40, 2375-2379 (1996).
31. Phaff, S. J., Tiddens, H. A., Verbrugh, H. A. & Ott, A. Macrolide resistance of Staphylococcus aureus and Haemophilus species associated with long-term azithromycin use in cystic fibrosis. J. Antimicrob. Chemother. 57, 741-746 (2006).